Comparison of serum lactate value with and without injection magnesium sulphate in sepsis

Comparison of Lactate clearance with and without administration of Intravenous Magnesium Sulphate in acute phase of sepsis -A randomised clinical trial - Nil

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/070763

Enrollment

150

Registered

2024-07-18

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R790- Abnormal level of blood mineral

Interventions

Intervention1: Injection Magnesium Sulphate: Group M who received Intravenous injection Magnesium Sulphate 2 gm iv to maintain serum magnesium of 2.5 mg/dl for 72 hours Control Intervention1: Normal S

Eligibility

Inclusion criteria

Inclusion criteria: Critically I’ll patients following sepsis 3 guidelines

Exclusion criteria

Exclusion criteria: Hypomagnesemia ,Chronic liver disease ,chronic kidney disease ,pregnant and lactating mother

Design outcomes

Primary

Measure	Time frame
Does Administration of Intravenous Magnesium Sulphate decreases the duration of lacatate clearance in acute phase of sepsis in first 72 hoursTimepoint: first 72 hours	—

Secondary

Measure	Time frame
Maintaing serum Magnesium at higher limit of Normal during acute phase of sepsis reduces SOFA score, APACHE score in acute phase of sepsis in admission ,24 hours ,48 hours & 72 hoursTimepoint: At admission,24 hours,48 hours & 72 hours	—

Countries

India

Contacts

Public ContactSrinidhi Srikanth

Park Hospital

Park.Hospital12@gmail.com9873932737

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026